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Objective To systematically review published literature
to estimate the magnitude of association between
premorbid constipation and later diagnosis of
Parkinson’s disease.
Background Constipation is a recognised non-motor
feature of Parkinson’s and has been reported to predate
diagnosis in a number of observational studies.
Methods A systematic review and meta-analysis was
carried out following the Meta-analysis Of Observational
Studies in Epidemiology (MOOSE) criteria. A literature
search was undertaken in December 2014 using
PubMed and the search terms ‘Parkinson’s disease’ and
‘constipation’. Articles were screened for suitability and
reviewed against inclusion and exclusion criteria. Studies
were included if they assessed constipation by means of
a structured questionnaire or if constipation/drugs used
to treat constipation were coded in patient medical
records. Data were extracted using a standardised
template and effect size estimates combined using a
fixed-effects model. Heterogeneity was explored with the
I2 statistic.
Results 9 studies were included in the meta-analysis,
with a combined sample size of 741 593 participants.
Those with constipation had a pooled OR of 2.27 (95%
CI 2.09 to 2.46) for developing subsequent Parkinson’s
disease compared with those without constipation. Weak
evidence for heterogeneity was found (I2=18.9%,
p=0.282). Restricting analysis to studies assessing
constipation more than 10 years prior to Parkinson’s
disease gave a pooled OR of 2.13 (95% CI 1.78 to
2.56; I2=0.0%).
Conclusions This systematic review and meta-analysis
demonstrates that people with constipation are at a
higher risk of developing Parkinson’s disease compared
with those without and that constipation can predate
Parkinson’s diagnosis by over a decade.
INTRODUCTION
Parkinson’s disease (PD) is the second most
common neurodegenerative disorder with a preva-
lence of approximately 0.4%—a figure which is
expected to double by 2040.1 PD is diagnosed
when motor features such as tremor, bradykinesia
and rigidity become overt, by which time approxi-
mately 50% of neurons within the substantia nigra
remain.2 Over the past two decades, a variety of
prodromes have been recognised and may comprise
a number of early non-motor symptoms including
those attributable to autonomic dysfunction, mood
and cognitive disturbance, sleep disorders and
sensory disruption.3 Greater understanding of these
early features may help the identification of indivi-
duals at higher risk of being diagnosed with PD,
some of whom may be candidates for neuroprotec-
tive drug trials.
Constipation, a consequence of autonomic dys-
function, is one of the most studied of the pro-
dromal symptoms of PD. A recent study of the
prevalence of selected non-motor symptoms before
and after diagnosis of PD found that constipation
was the second most common non-motor symptom
of PD after anosmia, with a prevalence of 50% in
established PD, and occurring prior to diagnosis in
approximately 20% of patients overall.4 To date,
only one meta-analysis has examined the magnitude
of risk associated with constipation and the later
development of PD, as part of a wider investigation
of risk and protective factors for PD.5 In this, data
were pooled from two studies giving an effect size
(ES) estimate of 2.34 for the development of PD in
people with constipation as compared with those
without. However, the confidence intervals (CI)
were relatively wide, with the true population esti-
mate potentially between 1.6 and 3.5 times higher.
Since this initial meta-analysis published in 2012,
several large cohort and case–control studies have
been published,6–10 contributing a further 10 697
PD cases, where there were previously only 545.
We have refined the ES estimate of the risk of
future PD in those that are constipated, as well as
undertaking analysis restricted to studies providing
risk estimates for constipation with onset ≥10 years
prior to PD diagnosis.
METHODS
Search strategy
The Meta-analysis Of Observational Studies in
Epidemiology (MOOSE) guidelines for systematic
review and meta-analysis of observational studies in
epidemiology were adhered to throughout this
study. Two researchers (KLA-C and AJN) independ-
ently undertook a literature search on the 7
December 2014 using PubMed and the search
terms ‘constipation’ and ‘Parkinson’s disease’. The
search was restricted to English articles, and titles
and abstracts were screened for their suitability.
Articles whose abstracts did not report on constipa-
tion and PD, or solely reported prevalence or man-
agement of constipation in established PD were
excluded. Full articles were then obtained and
reviewed to determine suitability for inclusion or
exclusion. Differences of opinion were resolved
through discussion. The reference lists of all full
articles included, as well as the references from
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reviews and meta-analyses identified in the original search, were
hand-searched for additional relevant titles which were then
subjected to the same filtering process described above.
Inclusion criteria
Published studies that met the following criteria were included:
(1) observational studies with a cohort or case–control design;
(2) cases were patients diagnosed with PD according to standard
clinical criteria, such as Queen Square Brain Bank Criteria;11 (3)
controls were healthy or had no history of neurological disease;
(4) controls were drawn from the same population as cases; (5)
constipation in controls was assessed over the same time period
as patients; (6) constipation was assessed by means of a struc-
tured questionnaire, or coded in patient medical records as con-
stipation or medication used to treat constipation and (7)
original data were reported.
Exclusion criteria
Abstracts, editorials, review articles, conference proceedings,
case reports and letters that did not report new data were
excluded. We also excluded studies that (1) reported on consti-
pation only after the diagnosis of PD; (2) reported on bowel
function other than constipation; (3) reported on the manage-
ment of constipation in PD; (4) did not provide adequate details
of the control group, or used inappropriate controls (chronically
ill or neurological disease); (5) did not report sufficient data to
calculate risk estimates; (6) recorded information differently for
cases and controls or (7) studied outcomes other than PD.
Data handling
Study characteristics and risk estimates were extracted from all
studies eligible for inclusion and tabulated in standard template
tables. Where risk estimates (relative risk (RR)/hazard ratio
(HR)/ odds ratio (OR)) were not available, data were reviewed
and an OR calculated where possible (odds in the exposed
divided by odds in the unexposed). Where risk estimates for
constipation were provided at multiple time points less than
10 years prior to PD diagnosis, the median time point was
chosen. A second risk estimates table was compiled to tabulate
data from those studies that had an average time between consti-
pation onset and PD diagnosis ≥10 years. Where risk estimates
were separated into multiple time points ≥10 years pre-PD diag-
nosis (ie, 7–12, 13–18 and 19–24 years6) and pooling of these
data was not possible, these estimates were excluded.
We used a definition of constipation of <3 bowel movements
(BMs) per week, a criterion within the Rome III definition for
functional constipation.12 Where this definition of constipation
was not used by studies, risk estimates corresponding to the
closest available definition were extracted. For the one study
where constipation was defined by laxative use as a proxy for
severity, the category likely to give the most conservative risk
estimate (‘mild’ laxative use) was chosen. Where constipation
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16 1997 Gonera Case–control 63 general practices 10 NK NA 60 58 Neurologist diagnosed, Queen Square
Brain Bank Criteria
ICPC defined General practice
record review
15 2001 Abbott Cohort Honolulu Heart Program 24 12 6790 96 6694 Hospital records/death certificates/
neurologist diagnosed
<1 BM per day (≤3 per
week) compared with daily
Structured
questionnaire
17 2009 Savica Case–control Rochester Epidemiology Project,
Olmsted County, Minnesota
38 >20 NA 196 196 Medical record review (2/4 cardinal
features excluding other causes).
Validated




6 2011 Gao Cohort Health Professionals Follow up
Study
6 NK 33 901 156 33 745 Neurologist diagnosed or 2/3 of cardinal
features excluding other causes
BM every 3 days or less




6 2011 Gao Cohort Nurses’ Health Study 24 NK 93 767 37 93 730 Neurologist diagnosed or 2/3 of cardinal
features excluding other causes
BM every 3 days or less




7 2014 Plouvier Case–control CMR database; University of
Nijmegen
2 NK 12 000 86 78 GP or neurologist diagnosed—coded
within CMR database
Diagnosis in the CMR
database
CMR record review
8 2014 Lin Cohort National Health Insurance
Database
5.5 NK 551 324 2336 548 988 Hospital discharge diagnosis or
neurologist diagnosed
Diagnosis in database and
use of laxatives
Database review
9 2014 Schrag Case–control Health Improvement Network UK
Primary care database
14 >10 NA 8166 46 755 Read code in database and ≥2 PD
medications
Read code in database or
laxative prescription
Database review
10 2014 Pont-Sunyer Case–control 11 outpatient clinics >10 >10 NA 109 107 Queen Square Brain Bank Criteria 3 months of <3 BMs per
week or straining
NMS questionnaire
*Abridged table; see supplementary table S1 for complete table.



























was coded in medical records as a binary term, it was not pos-
sible to ascertain the diagnostic criteria used but data were still
included within the meta-analysis.
Where figures were available that excluded patients enrolled
less than 2 years prior to PD diagnosis, these figures were pre-
ferred in order to avoid confounding by prevalent disease.
Where figures adjusted for laxative use, the unadjusted figures
were selected.
Where the above conditions were met and there still remained
a choice between risk estimates, the risk estimates matched or
adjusted for age and gender, which reflected the full range of
participants and did not have data missing, were used. Finally,
studies were assessed for quality using the Newcastle-Ottawa
Scale (NOS).13
Statistical analysis
Measures of effect were combined using standard meta-analysis
methods. ORs were used as an estimate of RRs/HRs where
necessary (given rare disease assumption) along with 95% CIs.
A pooled ES estimate was calculated using a fixed-effects model
in the absence of clear heterogeneity. Statistical heterogeneity
was explored using the I2 statistic based on a χ2 test of observed
ES in each study against the (expected) pooled estimate. The
prespecified significance level for heterogeneity was set at 5%.
Publication bias was assessed using the Egger test and a funnel
plot.14 Statistical analysis was undertaken in Stata V.13.
RESULTS
The literature search yielded 366 results (see figure 1). Of these,
47 were excluded as they were not written in English, and a
further 240 were excluded on the basis of their title and
abstract. Review of the remaining 79 full articles led to 72
exclusions based on criteria described above. Hand searching of
references of included studies and all reviews led to the inclu-
sion of one additional study, which brought the total number of
included studies to eight. One of the included studies6 described
two separate cohorts—one male (Health Professionals
Follow-up Study) and one female (Nurses’ Health Study), and
these were included as two distinct studies for the purposes of
analysis, bringing the total number of studies included in the
analysis to nine. Of these, four were prospective cohort
studies,6 8 15 and the remaining five had a case–control
design.7 9 10 16 17 Four of the five case–control studies utilised
information from formal patient medical records. The combined
sample size of the nine studies was 741 593.
Summary characteristics and risk estimates for all included
studies are provided in tables 1–3 and online supplementary
table S1. Studies were assessed for quality using the NOS and
the results of this can be viewed in online supplementary table
S2. With NOS quality criteria, all studies scored ≥6/9 and four
of the included studies scored 8/9.
Meta-analysis to pool data from all nine studies revealed a
positive association between constipation and subsequent diag-
nosis of PD (figure 2). The ES estimate for those with constipa-
tion and the association with PD was 2.27 (95% CI 2.09 to
2.46) compared with those without constipation. Weak evidence
for heterogeneity was found (I2=18.1%, p=0.282), and there
was no evidence for publication bias (p=0.757; see online sup-
plementary figure S4).
Case–control and cohort studies were analysed separately to
examine heterogeneity between estimates. The summary ES of
case–control studies was 2.24 (95% CI 2.05 to 2.46), while that
of cohort studies was 2.36 (95% CI 2.00 to 2.80). There was
no evidence for heterogeneity between these subgroups
(p=0.592).
The average time between exposure assessment and diagnosis
of PD varied greatly among these studies, ranging from <2 to
>20 years. When analysis was restricted to those risk estimates
corresponding to constipation with an onset of ≥10 years prior
to PD diagnosis (figure 3), a similarly strong positive association
was again found, with an ES of 2.13 (95% CI 1.78 to 2.56;
I2=0.0%, p=0.758).
Table 2 Risk estimates across all studies included in primary analysis
Reference Year Author Study design p Value RR HR OR CI lower CI upper
16 1997 Gonera Case–control 0.209 – – 0.45 0.13 1.57
15 2001 Abbott Cohort 0.013 2.30 – – 1.2 4.5
17 2009 Savica Case–control 0.0005 – – 2.48 1.49 4.11
6 2011 Gao—HPFS Cohort <0.0001 4.35 – – 1.80 10.5
6 2011 Gao—NHS Cohort 0.03 2.98 – – 1.09 8.14
7 2014 Plouvier Case–control 0.039 – – 3.32 1.1 10.4
8 2014 Lin Cohort <0.0001 – 2.29 – 1.91 2.74
9 2014 Schrag Case–control – 2.24 – – 2.04 2.46
10 2014 Pont-Sunyer Case–control <0.05 – – 2.7 1.4 5.2
HR, hazard ratio; OR, odds ratio; CI, confidence interval; RR, relative risk.
Table 3 Risk estimates corresponding to constipation ≥10 years pre-PD
Reference Year Author Study design Exposure to outcome (years) p Value RR HR OR CI lower CI upper
15 2001 Abbott Cohort 12 0.013 2.30 – – 1.2 4.5
17 2009 Savica Case–control >20 0.0005 – – 2.48 1.49 4.11
9 2014 Schrag Case–control >10 – 2.01 – – 1.62 2.49
10 2014 Pont-Sunyer Case–control >10 <0.05 – – 2.7 1.4 5.2
CI, confidence interval; HR, hazard ratio; OR, odds ratio; PD, Parkinson’s disease; RR, relative risk.
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DISCUSSION
This systematic review and meta-analysis offers confirmation for
the previously reported association between premorbid consti-
pation and subsequent diagnosis of PD. The consistency of
the association argues against the possibility that this could be
a chance finding and its plausibility is high given similar find-
ings in different study designs; both prospective and retro-
spective, with different biases, inherent assumptions and
methods of exposure ascertainment. The CI for the ES is
tight suggesting the true population risk estimate is in the
range of 2.0–2.5-fold. The observation holds for pooled ana-
lysis of studies assessing the period more than 10 years before
diagnosis.
Quantifying the magnitude of association between early non-
motor features and subsequent PD may underpin efforts to
identify higher risk participants for entry to interventional
studies with neuroprotective aims.18 Although the size of ele-
vated risk conveyed by constipation might be modest overall,
this is likely a consequence of constipation being a common
symptom encountered in older age, and that many who suffer
will not go on to be diagnosed with PD. However, the strength
of association is similar more than a decade before diagnosis
with PD, suggesting a long window of opportunity for interven-
tion, were certainty of future PD to be increased through com-
bination with other markers (clinical, imaging, laboratory) of
the prodrome. Of note, one of the included case–control studies
found significant associations with constipation predating PD
diagnosis by 20 years, but the CIs for the association were
wide.17
Three main possible underlying reasons for the association of
constipation with PD are: (1) constipation is a manifestation of
early PD within the bowel and therefore part of the disease
itself, (2) constipation is a risk factor for PD and it has a causal
association with subsequent disease, or (3) constipation and PD
are both outcomes of a common exposure.
Immunohistochemical studies have demonstrated the exist-
ence of abnormal deposits of α-synuclein within the submucosal
and myenteric plexuses of the enteric nervous system.19 20
While the pathophysiological basis for colonic dysmotility and
pelvic floor dysfunction that causes constipation in PD remains
Figure 2 Forest plot demonstrating increased PD risk in those with premorbid constipation as compared with those without (CI, confidence
interval; HR, hazard ratio; PD, Parkinson’s disease; RR, relative risk; OR, odds ratio).
Figure 3 Forest plot demonstrating increased risk of developing PD in those with constipation of duration ≥10 years as compared with those
without constipation (CI, confidence interval; PD, Parkinson’s disease; RR, relative risk; OR, odds ratio).
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unclear,21 the presence of these deposits raises the possibility of
making a tissue diagnosis of PD during life. Several studies have
reported positive findings from biopsies taken during routine
colonoscopy in patients with PD compared with controls.22 23
The investigation of gut biopsy in archival tissue obtained prior
to PD diagnosis in small numbers of participants was prompted
by the observation that constipation was an early non-motor
feature of PD.24 Subsequently, α-synuclein accumulation has
been detected in colonic biopsies taken up to 7 years before the
onset of motor symptoms.25
Endoscopic gastrointestinal biopsy remains an active area of
PD biomarker research, but there is now also growing interest in
the gut microbiome. In a recent pilot study, the abundance of
Prevotellaceae in faeces was significantly lower in patients with
PD compared with controls and positive associations were
found between abundance of Enterobacteriaceae and motor
symptoms of PD.26 Whether changes in gut flora are replicable
must now be elucidated through further study, and if so, the
matter of whether they are a cause or consequence of disease
must be determined since both could confound the association
between constipation and PD. Additional challenges lie in
understanding the impact of laxative use and dietary habits, and
these must be met before the microbiome could be considered a
potential biomarker of disease state.
Laxative use is an important covariate in the association
between constipation and PD, and requires some consideration.
If constipation was associated with PD by way of being a mani-
festation of PD, then adjusting for laxative use in the analysis
may underestimate the strength of this association. If, on the
other hand, constipation were a risk factor for PD, then strati-
fied analysis by laxative use would determine the strength of
association in those that did and did not use laxatives, allowing
an adjusted ES estimate to be calculated. However, this may be
inappropriate since it is feasible, albeit unlikely, that laxatives in
fact lie on the causal pathway between constipation and PD.
These issues may similarly apply to the role of diet, which is
known to be difficult to measure and quantify.
Lack of concordance between studies in their approach to
laxatives was a potential limitation of this study. Several of the
case–control studies included laxative use recorded in medical
records as a proxy for constipation, while others excluded laxa-
tive users from the definition of constipation or adjusted for
laxatives in secondary analyses. Given the ambiguity around the
role that laxatives might play in the association between consti-
pation and PD, where relevant, figures excluding laxative users
were used in preference to figures adjusted for laxative use. This
is in line with our conservative approach elsewhere during the
data handling process (using mild constipation in preference to
moderate or severe), and if it has any impact on the risk esti-
mate, it would be to underestimate it. Of note, one study pro-
vided risk estimates for later PD diagnosis for both the group
with constipation as a whole, and for the subset of this group
that required laxative treatment.17 These risk estimates closely
approximated each other, suggesting that laxative use may have
little additional effect on later PD diagnosis when compared
with constipation alone. However, the numbers included within
each group were small.
Other limitations of this study include the limits of the litera-
ture search: restricted to PubMed, to articles written in English,
and to the search terms ‘constipation’ and ‘Parkinson’s disease’,
which may conceivably have led to some missing studies.
However, the references of all full articles picked up in the
initial search were hand-searched for additional relevant studies,
and only one additional paper was identified via this strategy. A
broad range of study designs was included, with a variety of
methods employed to determine and define ‘constipation’. We
limited variability where possible by selecting the definitions
most in keeping with one another, and a definition in line with
the Rome III criteria for functional constipation.12 Where con-
stipation or laxative use was coded in medical records, the exact
definition of constipation in each case could not be determined.
However, despite the impact this could have had on variability
between study results, our analysis showed little evidence of het-
erogeneity between studies, and between case–control and
cohort subgroups as a whole, suggesting that the effect that dif-
ferent definitions of constipation and study designs had on risk
estimates did not differ greatly.
Recall bias is a concern when including results from some
case–control studies; however, only one of the nine included
studies adopted a retrospective design, whereby participants
were asked to recall the date of onset of a number of non-motor
symptoms. The introduction of recall bias in this particular
study was minimised by recruiting patients only recently diag-
nosed with PD, with a median time between PD diagnosis and
study evaluation of 1 month.10
The quality of the studies was assessed via means of the
NOS.13 All studies included in the main analysis had scores
≥6/9, and all studies in the secondary analysis (studies that
examined constipation over a decade before PD diagnosis) had a
score of 8/9 (see online supplementary table S2). Therefore, the
risk estimate that resulted from this analysis may also be viewed
as a fairly ‘stringent’ estimate, a result of the pooling of data
from only highest quality studies. A further benefit of the sec-
ondary analysis is that any participants with undiagnosed preva-
lent PD would likely not have been included, and so it avoids
potential bias that would arise in this scenario.
It should be noted that the risk estimates provided here are
more likely to underestimate the true magnitude of association
between constipation and later development of PD than over-
estimate it. This is because more conservative definitions of con-
stipation were selected where a choice was available. In future
studies, we recommend: (1) that a universal definition of consti-
pation is used where possible, such as <3 BMs per week in the
presence of other features (e.g. straining or hard stools), in line
with Rome III criteria; and (2) that measures of effect are deter-
mined for both constipation and laxative use and unadjusted
and stratum-specific measures of effect are reported to better
determine the association with each.
In conclusion, we pool data from 741 593 people across nine
studies to provide a consolidated risk estimate relating premorbid
constipation to a later diagnosis of PD. Our risk estimate suggests
that, compared with someone without, an individual with consti-
pation is at a 2.27-fold increased risk of developing PD, and this
increase in risk persists over a decade prior to diagnosis. This
updates previous risk estimates (with associated wide CIs) and pro-
vides information that will help ascertain those at increased risk of
PD and perhaps better understand the early stages of disease.
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